Key features and details
- Sensitivity: 30 ng/ml
- Range: 100 ng/ml - 3000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameInfliximab ELISA Kit
See all Infliximab kits
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15%
Sample typeSerum, Plasma
Assay typeSandwich (quantitative)
Range100 ng/ml - 3000 ng/ml
Sample specific recovery Sample type Average % Range Serum 85% - 115%
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Note: Infliximab ELISA kit ab237647 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Infliximab in the sample or standard. Results of samples can be determined directly using the standard curve.
PlatformMicroplate (12 x 8 well strips)
Storage instructionsStore at +4°C. Please refer to protocols.
Components 96 tests Micro ELISA Plate 1 unit Infliximab Standard S1 1 x 0.3ml Infliximab Standard S2 1 x 0.3ml Infliximab Standard S3 1 x 0.3ml Infliximab Standard S4 1 x 0.3ml Infliximab Standard S5 1 x 0.3ml Infliximab Standard S6 1 x 0.3ml Infliximab Standard S7 1 x 0.3ml Assay Buffer 1 x 50ml HRP-conjugate Probe 1 x 12ml TMB substrate 1 x 12ml Stop Solution 1 x 12ml Wash buffer (20X) 1 x 50ml Plate sealers 2 units
RelevanceInfliximab is a chimeric monoclonal antibody and used to treat auto- immune disorders. Infliximab reduces the amount of active human tumour necrosis factor alpha (hTNFa) in the body by binding to it and preventing it from signaling the receptors for TNFa on the surface of various cell types. TNFa is one of the key cytokines that triggers and sustains the inflammatory reactions. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis.
- human tumour necrosis factor alpha
ab237647 has not yet been referenced specifically in any publications.